Daxor Beheer

Beheer criteriumcontroles 3/4

De CEO Daxor is Michael Feldschuh, benoemd in Sep2016, heeft een ambtstermijn van 8.17 jaar. bezit rechtstreeks 3.36% van de aandelen van het bedrijf, ter waarde $ 1.46M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6 jaar en 6.1 jaar.

Belangrijke informatie

Michael Feldschuh

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.2yrs
Eigendom CEO	3.4%
Management gemiddelde ambtstermijn	6yrs
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Michael Feldschuh's beloning veranderd ten opzichte van Daxor's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$2m
Mar 31 2024	n/a	n/a	US$984k
Dec 31 2023	n/a	n/a	US$281k
Sep 30 2023	n/a	n/a	US$2m
Jun 30 2023	n/a	n/a	US$4m
Mar 31 2023	n/a	n/a	US$5m
Dec 31 2022	US$100k	US$100k	US$5m
Sep 30 2022	n/a	n/a	US$5m
Jun 30 2022	n/a	n/a	US$4m
Mar 31 2022	n/a	n/a	US$5m
Dec 31 2021	US$100k	US$100k	US$5m
Sep 30 2021	n/a	n/a	US$3m
Jun 30 2021	n/a	n/a	US$294k
Mar 31 2021	n/a	n/a	-US$706k
Dec 31 2020	US$100k	US$100k	-US$2m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$2m
Dec 31 2019	US$100k	US$100k	-US$496k
Sep 30 2019	n/a	n/a	-US$149k
Jun 30 2019	n/a	n/a	US$197k
Mar 31 2019	n/a	n/a	-US$344k
Dec 31 2018	US$100k	US$100k	-US$886k
Sep 30 2018	n/a	n/a	-US$1m
Jun 30 2018	n/a	n/a	-US$1m
Mar 31 2018	n/a	n/a	-US$1m
Dec 31 2017	US$100k	US$100k	-US$1m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Michael redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: De vergoeding van Michael is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Michael Feldschuh (55 yo)

8.2yrs

Tenure

US$100,000

Compensatie

Mr. Michael Richard Feldschuh has been the Chief Executive Officer and President of Daxor Corp. since September 21, 2016. Mr. Feldschuh served as Acting Chief Executive Officer and President of Daxor Corp....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Feldschuh	Chief Scientific Officer & Director	no data	US$127.92k	0.081% $ 35.1k
Michael Feldschuh	Chairman	8.2yrs	US$100.00k	3.36% $ 1.5m
Robert Michel	CFO, Chief Compliance Officer & Corporate Secretary	6.2yrs	geen gegevens	0.23% $ 101.6k
Linda Cooper	Vice President of Development & Operations	1.8yrs	geen gegevens	geen gegevens
Kathryn Kornafel	Senior VP of Marketing & Commercial Development	6.4yrs	geen gegevens	geen gegevens
Guido Manzo	Vice President of Sales	5.8yrs	geen gegevens	geen gegevens
Jean Oertel	Senior Vice President Commercialization & Customer Experience	no data	geen gegevens	geen gegevens
John Jefferies	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DXR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Feldschuh	Chief Scientific Officer & Director	7.8yrs	US$127.92k	0.081% $ 35.1k
Michael Feldschuh	Chairman	11.8yrs	US$100.00k	3.36% $ 1.5m
Phillip Frost	Chairman of Medical Advisory Board	no data	geen gegevens	geen gegevens
Caleb DesRosiers	Independent Director	2.8yrs	US$1.75k	0.065% $ 28.4k
Fred Gilbert	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
James Brassel	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Edward Feuer	Independent Director	8.8yrs	US$2.13k	0.021% $ 9.0k
Henry Cremisi	Independent Director	4.4yrs	US$1.13k	0% $ 0
Joy Goudie	Independent Director	4.4yrs	US$2.13k	0.0062% $ 2.7k

6.1yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DXR wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

Daxor Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Daxor Corporation, Annual General Meeting, Jul 15, 2024

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jul 11, 2023

Daxor Corporation, Annual General Meeting, Jun 23, 2022

Recent updates

Daxor Corporation, Annual General Meeting, Jul 15, 2024

Nasdaq Staff Determines Daxor Complies with Nasdaq’s Audit Committee Requirement Set in Listing Rule 5605

Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

New minor risk - Profit margin trend

New minor risk - Financial data availability

Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis

Investor sentiment deteriorates as stock falls 16%

Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

Investor sentiment improves as stock rises 20%

Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers

Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting

JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®

Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jul 11, 2023

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Investor sentiment deteriorates as stock falls 26%

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorated over the past week

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $2.000007 million.

Daxor Corporation Study Demonstrates Significant Clinical Utility of Daxor's Blood Volume (Bva-100(R)) Diagnostic in the Evaluation of Heart Failure

Investor sentiment deteriorated over the past week

Daxor Corporation Announces New Data Validating Benefits of BVA-100 Diagnostic Blood Test in Reducing Hospital Length of Stay (LOS) for Heart Failure (HF) Patients

Daxor Corporation to Report Q2, 2022 Results on Aug 25, 2022

Daxor reports Q2 results

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Daxor Corporation, Annual General Meeting, Jun 23, 2022

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

Daxor Corporation Announces New Data Demonstrating the Importance and Clinical Utility of Daxor’s Bva-100 Blood Test in Heart Failure (Hf) Patients Published in the Journal of Cardiac Failure

Daxor Corporation Announces Patient Enrollment Completion and Updates Data Analysis

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Daxor Corporation Provides Update on American College of Cardiology (ACC) Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

Daxor Corporation Announces the Initiation of A Multi-Center Clinical Trial with Two Veterans Affairs Medical Centers to Evaluate Blood Volume Analysis Guided Management of Acute Decompensated Heart Failure Utilizing the BVA-100 Blood Test

Daxor Corporation Announces Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

Daxor Corporation Announces Novel Fluorescent Tracer and Phase-Two US Air Force Contract Award of $750,000 for Point-Of-Care Optical Blood Volume Analyzer

Revenue and earnings miss expectations

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

New 90-day low: US$11.49

Daxor Corporation Announces New Data from the University of Hawaii John A. Burns School of Medicine Showing the BVA-100 Blood Test

Daxor Corporation Announces New Distribution Agreement with L1 Enterprises Government Distributor

New 90-day low: US$12.10

New 90-day low: US$12.55

Wake Forest Baptist Health Joins Multicenter Covid-19 Bva-100 Blood Test Study

New 90-day low: US$13.85

New 90-day low: US$14.61

Daxor Corporation Announces Compelling New Data Demonstrating Further Beneficial Use of Blood Volume Analysis Technology Presented During the Heart Failure Society of America’s Virtual Annual Scientific Meeting 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd